The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

The new drug forces fat cells to produce more energy and doesn't impact appetite or muscle mass, unlike some existing ...

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...

Durham-based TruTechnologies has secured a strategic growth investment from LLR Partners to accelerate the expansion of its real-time clinical trial oversight solutions and fuel the next phase of ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical ...

TherVacB, a novel therapeutic vaccine for chronic hepatitis B developed under the leadership of Helmholtz Munich, has entered its first clinical trial in patients. Following a successful phase 1a ...

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization ...

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate ...

New findings confirm that partial-breast and reduced-dose radiotherapy effectively treat low-risk early-stage breast cancer ...